- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04684108
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
A Phase 1 Study of SG301 in Subjects With Hematological Malignancies
Study Overview
Status
Intervention / Treatment
Detailed Description
After a screening period of up to 28 days for each study phase, qualified patients will be enrolled to receive their assigned dose of SG301, administered weekly for the first 2 cycles and every 2 weeks thereafter, until disease progression or intolerable toxicity, starting of a new anticancer treatment, withdrawal of consent, lost to follow up, death, or end of the study, whichever occurs first.
The study consists of a dose escalation phase (Phase 1a) and a dose expansion phase (Phase 1b) in subjects with relapsed or refractory multiple myeloma and other hematological malignancies.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Lingling Liu
- Phone Number: 86-13466612412
- Email: liulingling@sumgenbio.com
Study Locations
-
-
Anhui
-
Bengbu, Anhui, China, 233099
- The First Affiliated Hospital of Bengbu Medical College
-
-
Beijing
-
Beijing, Beijing, China, 100020
- Affiliated Beijing Chaoyang Hospital of Capital Medical University
-
Beijing, Beijing, China, 100032
- Beijing Jishuitan Hostipal
-
-
Guangzhou
-
Shenzhen, Guangzhou, China, 518025
- Shenzhen Second People's Hospital
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050011
- The Fourth Affiliated Hospital of Hebei Medical University
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430062
- Wuhan University Central South Hospital
-
Xiangyang, Hubei, China, 441021
- Xiangyang Central Hospital
-
-
Jiangsu
-
Wuxi, Jiangsu, China, 214125
- Wuxi Central Hospital
-
-
Liaoning
-
Shenyang, Liaoning, China, 110002
- The First Affiliated Hospital of China Medical University
-
Shenyang, Liaoning, China, 110136
- Shengjing Hospital affiliated to China Medical University
-
-
Shandong
-
Jinan, Shandong, China, 250063
- Qilu Hospital of Shandong University
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030032
- Shanxi Norman Bethune Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- The second affiliated hospital of zhejiang university school of medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Understand and voluntarily sign the informed consent form (ICF).
- Age ≥18 years.
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2.
- Expected survival time of ≥3 months.
Patients with histologically or cytologically confirmed hematological malignancies who are relapsed or refractory to or intolerant of standard therapies.
For patients with multiple myeloma: should be relapsed or refractory multiple myeloma with measurable disease
- Adequate organ function
- Toxicity caused by prior anti-tumor therapy recovered to Grade 0 to 1 (CTCAE 5.0), except for alopecia, controlled Grade ≤2 sensory neuropathy, lymphocytopenia, and endocrine disorders.
- Female patients of childbearing potential and male patients whose female partners are of childbearing potential need to use at least one approved contraceptive (e.g., intrauterine device, pill, or condom) during study treatment and for at least 6 months (180 days) after the last dose; female patients of childbearing potential must have a negative blood human chorionic gonadotropin (HCG) test during screening period and must not be lactating.
Exclusion Criteria:
Patient Exclusion Criteria:
- Presence of central nervous system metastatic lesions.
- uncontrolled cardiac disease requiring treatment, congestive heart failure NYHA III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months.
- Active infection requiring antimicrobial therapy within 2 weeks prior to study drug administration.
- Patients with active viral hepatitis (any etiology) are excluded.
- Anticancer therapy within 5 half-lives or 2 weeks (whichever is longer)
- Primary refractory to previous anti-CD38 therapy.
- Major surgery within 4 weeks prior to study entry.
- Prior or concurrent malignancy within 2 years prior to entry, other than adequately controlled skin basal cell carcinoma, cervical carcinoma in situ, breast carcinoma in situ, skin squamous cell carcinoma.
- Any other condition that, in the opinion of the Investigator, may lead to inappropriate participation in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SG301
SG301 monotherapy intravenous (IV) infusion
|
Phase 1a will use an accelerated titration and 3+3 design with 9 dose cohorts: 0.005 mg/kg, 0.05 mg/kg,0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg and 16 mg/kg by IV infusion.
Accelerated titration (i.e., 1 patient each) will be applied to the first 3 cohorts.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events
Time Frame: Through study completion, an average of one year
|
Number and percentage of AE which is calculated by worst CTCAE grade by CTCAE 5.0
|
Through study completion, an average of one year
|
MTD/MAD/ RP2D
Time Frame: Through study completion, an average of one year
|
To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) for intravenous (IV) administration of SG301 in patients with relapsed or refractory multiple myeloma and other hematological malignancies; To preliminarily determine the recommended Phase 2 dose (RP2D) of SG301 given intravenously in patients with relapsed or refractory multiple myeloma and other hematological malignancies.
|
Through study completion, an average of one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK): AUC
Time Frame: Through study completion, an average of one year
|
The area under the curve (AUC) of serum concentration of the drug after the administration
|
Through study completion, an average of one year
|
Pharmacokinetics (PK): Cmax
Time Frame: Through study completion, an average of one year
|
Maximum concentration(Cmax) of the drug after administration
|
Through study completion, an average of one year
|
Pharmacokinetics (PK): limination half-life (T 1/2)
Time Frame: Through study completion, an average of one year
|
Descripition: limination half-life (T 1/2) of the drug after administration
|
Through study completion, an average of one year
|
receptor occupancy (RO)
Time Frame: Through study completion, an average of one year
|
receptor occupancy (RO) of CD38 on the surface of peripheral blood cells
|
Through study completion, an average of one year
|
Immunogenicity endpoints
Time Frame: Through study completion, an average of one year
|
levels of anti-drug antibodies (ADAs) and neutralizing antibodies (tested in ADA-positive samples only).
|
Through study completion, an average of one year
|
Efficacy endpoints
Time Frame: Through study completion, an average of one year
|
objective response rate (ORR)
|
Through study completion, an average of one year
|
Collaborators and Investigators
Investigators
- Study Director: Lingling Liu, Hangzhou Sumgen Biotech Co., Ltd.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Neoplasms by Site
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms
- Hematologic Neoplasms
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- CSG-301-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed or Refractory Multiple Myeloma
-
BeBetter Med IncCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Non-Hodgkin's LymphomaChina
-
AmgenActive, not recruitingRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid LeukemiaUnited States, Australia, Japan, Germany, Canada
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Non-Hodgkin Lymphoma | Relapsed or Refractory Chronic Lymphocytic LeukemiaUnited Kingdom, Spain, France, Australia
-
Oncopeptides ABTerminatedRelapsed Multiple Myeloma | Relapsed-Refractory Multiple MyelomaSerbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
-
Novartis PharmaceuticalsCompletedRefractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple MyelomaUnited States
-
Oncopeptides ABTerminatedRelapsed and/or Relapsed-refractory Multiple MyelomaUnited States, Netherlands, Denmark, Sweden, Italy
-
University of NebraskaM.D. Anderson Cancer CenterTerminatedCabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaMultiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple MyelomaUnited States
-
University of LeedsCompletedRelapsed or Refractory Multiple MyelomaUnited Kingdom
-
Memorial Sloan Kettering Cancer CenterExelixisCompletedRelapsed or Refractory Multiple MyelomaUnited States
-
Janssen Research & Development, LLCRecruitingRelapsed or Refractory Multiple MyelomaKorea, Republic of, Italy, Germany, France, Japan, Israel, Belgium, Denmark, Sweden, Canada, Spain, Czechia, Poland, Australia, Netherlands, United Kingdom, India, China
Clinical Trials on SG301
-
Hangzhou Sumgen Biotech Co., Ltd.RecruitingSystemic Lupus Erythematosus (SLE)China